NIH-funded research NIH-funded research

Finding blood markers for Adrenomyeloneuropathy

Official title: Discovery and validation of multi-omic plasma biomarkers for Adrenomyeloneuropathy

Funded at Hugo W. Moser Res Inst Kennedy Krieger · NIH-10870302 · Data updated 2026-11-12

This study is looking for new blood tests that can help track how Adrenomyeloneuropathy (AMN) changes over time and predict future symptoms, so if you have AMN, your blood samples could help researchers find better ways to understand and manage the condition.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionHugo W. Moser Res Inst Kennedy Krieger
NIH-funded
Lab location1 site (Baltimore, United States)
Project startAugust 1, 2024
Project endJune 30, 2026
Funding year2024
Award (this year)$829,626
NIH project number1R61NS131928-01A1
Project IDNIH-10870302 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals diagnosed with Adrenomyeloneuropathy or those who carry mutations in the ABCD1 gene.

Less likely to help

Patients without a diagnosis of Adrenomyeloneuropathy or those not carrying ABCD1 mutations may not benefit from this research.

What this research studies

This research aims to discover and validate new blood biomarkers for Adrenomyeloneuropathy (AMN), a neurological condition linked to genetic mutations. By using advanced techniques that analyze various biological molecules in blood plasma, the study seeks to identify markers that can help monitor disease progression and predict future symptoms. The approach combines omics technologies with machine learning to enhance the accuracy of these biomarkers. Patients will provide blood samples over time, allowing researchers to track changes and correlate them with clinical outcomes.

Why it matters

Potential benefit: If successful, this research could lead to better monitoring and prediction of disease progression in patients with Adrenomyeloneuropathy.

How similar studies have gone: Previous research has shown promise in using omics approaches to identify biomarkers for other neurological conditions, suggesting potential success for this novel approach.

Where this research is happening

  • Hugo W. Moser Res Inst Kennedy Krieger
    Baltimore, United States
    Active

Researchers

  • Principal investigator: Fatemi, S. Ali — Hugo W. Moser Res Inst Kennedy Krieger
  • Study coordinator: Fatemi, S. Ali

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.